MOC Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł8.10 |
| 52 Week High | zł16.70 |
| 52 Week Low | zł7.60 |
| Beta | 2.61 |
| 1 Month Change | -3.57% |
| 3 Month Change | -14.83% |
| 1 Year Change | -46.14% |
| 3 Year Change | -72.26% |
| 5 Year Change | -37.45% |
| Change since IPO | -72.07% |
Recent News & Updates
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?
Aug 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Shareholder Returns
| MOC | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 0.6% | -1.1% | 4.0% |
| 1Y | -46.1% | 29.5% | 9.7% |
Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned 29.5% over the past year.
Return vs Market: MOC underperformed the Polish Market which returned 9.7% over the past year.
Price Volatility
| MOC volatility | |
|---|---|
| MOC Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in PL Market | 11.5% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: MOC has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: MOC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 102 | Marcin Szumowski | molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| MOC fundamental statistics | |
|---|---|
| Market cap | zł163.65m |
| Earnings (TTM) | -zł31.29m |
| Revenue (TTM) | zł2.92m |
56.1x
P/S Ratio-5.2x
P/E RatioIs MOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOC income statement (TTM) | |
|---|---|
| Revenue | zł2.92m |
| Cost of Revenue | zł3.41m |
| Gross Profit | -zł489.91k |
| Other Expenses | zł30.80m |
| Earnings | -zł31.29m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | -1.55 |
| Gross Margin | -16.78% |
| Net Profit Margin | -1,071.83% |
| Debt/Equity Ratio | 0% |
How did MOC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 18:42 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecure S.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Lukasz Kosiarski | Ipopema Securities S.A. |